Abstract
The search for nonstimulant medications for attention-deficit/hyperactivity disorder (ADHD) continues. In a manufacturer-sponsored, two-phase study, investigators performed the first long-term efficacy study of guanfacine extended-release (GXR), an alpha-2-adrenergic agonist, at 67 sites in the U.S., Europe, and Canada. First, 526 school-age participants with ADHD (mean age, 11; 84% with combined subtype) received open-label GXR; …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
